Russian FederationTuberculosis profile
Population  2015 143 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 15 (15–16) 11 (10–11)
Mortality (HIV+TB only) 1.5 (<0.01–7.4) 1 (0–5.2)
Incidence  (includes HIV+TB) 115 (98–132) 80 (69–92)
Incidence (HIV+TB only) 11 (9.3–13) 7.9 (6.5–9.4)
Incidence (MDR/RR-TB)** 60 (49–71) 42 (34–49)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 4.6 (2.8–6.4) 31 (19–44) 36 (21–50)
Males 4.4 (3–5.8) 74 (58–90) 79 (61–96)
Total 9 (6.8–11) 106 (96–115) 115 (98–132)
TB case notifications, 2015  
Total cases notified 130 904
Total new and relapse 99 590
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status  
          - % pulmonary 93%
          - % bacteriologically confirmed among pulmonary 49%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 87% (75–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.15 (0.11–0.19)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 6 407  
          - on antiretroviral therapy    
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  42 000
(35 000–48 000)
Estimated % of TB cases with MDR/RR-TB 22% (14–25) 53% (40–59)  
% notified tested for rifampicin resistance 38% 31% 46 641
MDR/RR-TB cases tested for resistance to second-line drugs    
Laboratory-confirmed cases MDR/RR-TB: 17 132, XDR-TB:
Patients started on treatment **** MDR/RR-TB: 26 756, XDR-TB: 1 205
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 69% 77 136
Previously treated cases, excluding relapse, registered in 2014 42% 5 790
HIV-positive TB cases, all types, registered in 2014    
MDR/RR-TB cases started on second-line treatment in 2013 48% 18 213
XDR-TB cases started on second-line treatment in 2013 26% 1 965
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2016  
National TB budget (US$ millions) 1 385
Funding source: 100% domestic, 0% international, 0% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-10 Data: www.who.int/tb/data